Article Text

Download PDFPDF

Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom
Free
  1. Z Zhou,
  2. R Althin,
  3. B S Sforzolini,
  4. R Dhawan
  1. Pharmacia Corporation, Pfizer Inc, 100 Route 206 North, Mail Stop 133, Peapack, NJ 07977, USA
  1. Correspondence to: Zhiyuan Zhou PhD Pfizer Inc, 100 Route 206 North, Mail Stop 133, Peapack, NJ 07977, USA; Zhiyuan.Zhoupfizer.com

Abstract

Aim: To determine utilisation patterns and calculate treatment failure and discontinuation rates in patients with open angle glaucoma treated in the United Kingdom with any of six groups of intraocular pressure (IOP) lowering agents.

Methods: The UK General Practice Research Database was used to identify newly diagnosed (after 1 January 1997) open angle glaucoma patients who were naive to therapy with any of six index drug groups: carbonic anhydrase inhibitors, latanoprost, miotics, sympathomimetics, timolol, and other (non-timolol) β blockers. Analyses included drug treatment data for 1 year following diagnosis. Outcomes were (1) time to therapy failure, defined as either change in index drug (replacement or addition of therapy) or patient referral for surgery, and (2) time to therapy discontinuation, defined as either therapy failure or no refill of the index drug in a period twice that covered by the first prescription fill. Cox proportional hazard regression and Kaplan-Meier and life table methods were used to compare groups.

Results: Among the 2001 eligible patients, a β blocker other than timolol was the most widely prescribed (42%), followed by timolol (32%), carbonic anhydrase inhibitors (10%), and latanoprost (7%). Compared to latanoprost, those treated with any alternative agent were significantly more likely to fail (p⩽0.005 for each comparison) and to discontinue (p⩽0.05 for each comparison) therapy. Failure rates ranged from 13% (latanoprost) to 45% (sympathomimetics), and discontinuation rates ranged from 30% (latanoprost) to 63% (miotics).

Conclusion: Latanoprost treated patients demonstrated lower rates of therapy failure and therapy discontinuation compared with patients treated with other widely used IOP lowering medications, including β blockers.

  • GPRD, General Practice Research Database
  • IOP, intraocular pressure
  • OXMIS, Oxford Medical Information System
  • latanoprost
  • open angle glaucoma
  • persistency
  • utilisation
  • GPRD, General Practice Research Database
  • IOP, intraocular pressure
  • OXMIS, Oxford Medical Information System
  • latanoprost
  • open angle glaucoma
  • persistency
  • utilisation

Statistics from Altmetric.com

Footnotes

  • This research was supported by Pharmacia Corporation, a Pfizer company.

  • At the time this research was conducted, the authors were employees of Pharmacia Corporation, a Pfizer company.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.